conference call icon 16th Annual Rodman & Renshaw
Global Investment Conference Webcast

September 9, 2014
1:15 PM EDT, New York Palace Hotel, New York, NY
 

Vision, Integrity, Expertise

Soligenix, Inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD), and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.

Non Confidential Introduction
to ThermoVax™

January 2014

View the presentation (pdf)
Corporate Presentation
September 25, 2014


View the presentation (pdf)

Latest News
Partnering with Us

Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of HSC transplant, supportive cancer care, gastrointestinal and biodefense.

Learn More >